Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076121 | 0.86 | EGLN1 (0.43) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL522203 | 0.78 | EGLN1 (0.70) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL5141913 | 0.78 | ABCG2 (0.41) | EGLN1FTOBBOX1 | |
| SCHEMBL5815317 | 0.78 | KDM4E (0.46) | EGLN1FTOBBOX1 | |
| SCHEMBL522733 | 0.74 | ESR1 (0.44) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL523385 | 0.74 | EGLN1 (0.70) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL15832853 | 0.72 | EGLN2 (0.47) | EGLN1EGLN2KDM5B | |
| SCHEMBL525577 | 0.70 | EGLN1 (0.48) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL5934937 | 0.70 | EGLN1 (0.51) | EGLN1FTOBBOX1EGLN2THRA | |
| SCHEMBL522756 | 0.70 | EGLN1 (0.47) | EGLN1EGLN2THRATHRBKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885FTO 1983/4885BBOX1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.